Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11937853 | 0.88 | JMJD6 (0.47) | JMJD6TSHRMEN1KMT2AKDM4E | |
| SCHEMBL2249995 | 0.84 | TSHR (0.46) | TSHRMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2025343 | 0.82 | SOS1 (0.40) | JMJD6TSHRKMT2AKDM4EALDH1A1 | |
| SCHEMBL19329324 | 0.81 | DPP4 (0.45) | TSHRMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL18916810 | 0.81 | JMJD6 (0.56) | JMJD6TSHRMEN1KMT2AKDM4E | |
| SCHEMBL24746841 | 0.81 | ALDH1A1 (0.49) | TSHRMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21530434 | 0.81 | JMJD6 (0.56) | JMJD6TSHRMEN1KMT2AKDM4E | |
| SCHEMBL30427332 | 0.81 | DPP4 (0.45) | TSHRMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29709735 | 0.81 | NPC1 (0.46) | TSHRMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL18341514 | 0.81 | NPC1 (0.46) | TSHRMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021032323-A1 | FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES | GALAPAGOS NV (BE) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032323-A1 | FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES | GALAPAGOS NV (BE) | 2021-02-25 | — | — | WO | disclosed |
| EP-3782997-A1 | FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES | Galapagos N.V. (BE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3782997-A1 | FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES | Galapagos N.V. (BE) | 2021-02-24 | — | — | EP | disclosed |
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8227500-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2133331-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, CBR1 | JMJD6 605/4885TSHR 2691/4885MEN1 3974/4885 |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | XDH, DAO, DDO | JMJD6 639/4885TSHR 1777/4885MEN1 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.